Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Associate Professor Puneet Plaha of the Nuffield Department of Surgical Sciences has been awarded a £1.98 million NIHR Health Technology Assessment (HTA) grant to lead a five-year clinical trial addressing one of the most critical questions in brain cancer care.

Brain tumour surgery

Developed with Mr Chris McKinnon, Academic Clinical Lecturer in Neurosurgery, and in collaboration with the teams at the Surgical Interventions Trials Unit (SITU) and Oxford Clinical Trials Research Unit (OCTRU), the new UK multi-centre randomised controlled trial (RCT) — named RECURRENT-GB — will explore whether surgery can improve quality of life for patients when glioblastoma (a type of brain cancer) comes back after treatment.

Glioblastoma is a terminal disease. On average, people diagnosed with it live for about 18 months. Treatment usually starts with surgery to remove as much of the tumour as possible, followed by radiation and chemotherapy to slow its growth. However, the cancer almost always returns, and doctors aren't sure about the best way to treat it at that point. Specifically, it's unclear whether having another surgery alongside medication is more effective than medication alone.

Associate Professor Plaha, who is the Chief Investigator, said: 'Glioblastoma is one of the most aggressive brain cancers, and when it returns, we face difficult decisions on how best to help patients. This trial will provide crucial evidence to determine whether repeat surgery can improve quality of life and outcomes for those battling this disease. We are hopeful that RECURRENT-GB will bring clarity to this question and ultimately guide future treatment strategies.'

RECURRENT-GB is scheduled to launch in early 2026 and will be coordinated by SITU. It will complement and build on insights gained from Oxford’s ongoing FUTURE-GB study — a £1.7 million NIHR EME funded trial running from 2020 to 2027 which is also lead by Associate Professor Plaha as Chief Investigator. The trial is investigating the most effective surgical techniques to achieve maximal tumour removal during the initial presentation of glioblastoma.

 

Read the story on the Nuffield Department of Surgical Sciences website.

Similar stories

Oxford’s OrganOx wins the MacRobert Award 2025

The Royal Academy of Engineering has announced that OrganOx has won the £50,000 MacRobert Award, the longest running and most prestigious prize for UK engineering innovation, for its life-saving technology that is supporting more organ transplants and helping to cut waiting lists.